|
Found 11 result(s) FROM 1963 pages containing the term 'Cymbalta'.
Wednesday Mar 03, 2010
Patients Speak Out About the Pain of Fibromyalgia
Sometimes the best way to learn about a disease is to listen to the patients who suffer from it...
Thursday Sep 17, 2009
Lilly's Cymbalta Maintains Low Back Pain Relief
Data reported at a European pain meeting show that Cymbalta® (duloxetine) maintains relief of low back pain for 41 weeks...
Thursday Feb 26, 2009
Pfizer Stops Work on Esreboxetine for FM
Pfizer has stopped development of esreboxetine, which was in phase II trials for fibromyalgia...
Tuesday Feb 03, 2009
Lilly to Pursue OA Pain Indication for Cymbalta
Will OA join depression and fibromyalgia as Cymbalta indications?...
Tuesday Jan 20, 2009
Tricyclic Antidepressants Best for Fibromylagia
Some antidepressants can dramatically improve fibromyalgia symptoms...
Monday Nov 10, 2008
Lilly Reports European CHMP Adopts Negative Opinion on Cymbalta® for the Treatment of Fibromyalgia
The European CHMP has adopted a negative opinion on a Cymbalta® (duloxetine hydrochloride) application for the treatment of fibromyalgia, recommending the refusal of a change to the marketing authorization for Cymbalta/Xeristar 30 mg and 60 mg gastroresistant capsules...
Tuesday Jun 17, 2008
Cymbalta® Approved for Fibromyalgia
The antidepressant Cymbalta® (duloxetine) has been approved by the US FDA to treat fibromyalgia…
Friday Jun 13, 2008
60-Week Safety Data Reassuring for Duloxetine in Fibromyalgia
Duloxetine is safe and tolerable for long-term use in the treatment of fibromyalgia (FM)...
Tuesday Feb 19, 2008
Duloxetine, Milnacipran Studies in Fibromyalgia Reported
Duloxetine (Lilly's Cymbalta®) and milnacipran (Cypress Bioscience's Ixel®) studies report promising but mixed results...
Thursday Aug 23, 2007
Lilly Seeks Approval From US FDA for Cymbalta® (duloxetine hydrocholoride) in Fibromyalgia
Eli Lilly and Co announced that it has submitted a supplemental new drug application (sNDA) to the US FDA for Cymbalta® (duloxetine hydrocholoride), a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), for the management of fibromyalgia...
Wednesday Jun 21, 2006
EULAR Fibromyalgia Recommendations Surprisingly Upbeat
Far from being a hard-to-treat condition, fibromyalgia is yielding to a whole range of pharmacological and nonpharmacological therapies, according to a review presented by Ernest H. Choy, MD, at the 2006 EULAR Meeting...
|
